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ABSTRACT
Escherichia coliurinary tract isolateswere collected in 1997–2003 fromNıˆmesUniversityHospital in order to
investigate long-term trends in antibiotic resistance and to explore the relationship between antibiotic use
and the emergence of resistance. Time-series analysis (ARIMA models) and dynamic regression models
were used to investigate relationships between antibiotic use and resistance to oﬂoxacin and ciproﬂoxacin.
Signiﬁcant increases were seen in the frequency of oﬂoxacin (8.9 to 16.7%) and ciproﬂoxacin resistance
(6.2 to 10.1%) (p < 0.001). Using multivariate dynamic regression analysis, it was found that an increased
use of one deﬁned daily dose (DDD) ⁄ 1000 patient-days for oﬂoxacin, ciproﬂoxacin and norﬂoxacin
induced average increases of 0.81%, 0.65% and0.53% inE. colioﬂoxacin resistance (p < 0.01),with average
delays of 4, 4 and 6 months, respectively. An increase of 1 DDD ⁄ 1000 patient-days of ciproﬂoxacin,
oﬂoxacin and norﬂoxacin use induced increases of 0.73%, 0.82% and 0.63% in E. coli ciproﬂoxacin
resistance (p < 0.01), with average delays of 4, 4 and 5 months, respectively. The use of nalidixic acid was
not associated signiﬁcantly with an increase in resistance to ﬂuoroquinolones by multivariate analysis.
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INTRODUCTION
There is a growing consensus that the rapidly
increasing emergence and dissemination of anti-
biotic resistance necessitates increased surveil-
lance based on larger data sets [1]. According to
some infectious diseases societies [2,3], the collec-
tion of local resistance rate information through
ongoing surveillance is particularly important to
estimate changes in the susceptibility of patho-
gens. Hospital surveillance programmes are useful
in devising local directives for rational antibiotic
use and hospital infection control measures.
Escherichia coli is the primary urinary tract
pathogen, accounting for 75–90% of isolates from
uncomplicated urinary tract infections (UTIs) [4].
Several studies have shown increasing resistance
to ﬂuoroquinolones among E. coli isolates after
widespread use of ﬂuoroquinolones as UTI
therapy or as prophylaxisis for patients with
granulocytopenia and cirrhosis [5–7]. Some stud-
ies have suggested that the use of a variety of
antibiotics should be taken into account when
evaluating the relationship between consumption
and antibiotic resistance [8,9]. However, these
studies have used linear regression models that
are not appropriate for analysing data that may
be non-linear. Thus, Monnet et al. [10] have
suggested time-series analysis techniques which
may prove helpful in analysing temporal rela-
tionships between the use of several antibiotics
and resistance.
The objectives of the present studywere to assess
long-term antibiotic resistance trends among E. coli
isolates and to use dynamic regression (DR)
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analysis to investigate the temporal relationship
between the use of antibiotics and the evolution of
ﬂuoroquinolone resistance during 1997–2003.
MATERIALS AND METHODS
Hospital setting
Nıˆmes University Hospital has 1659 beds, including 858 acute-
care beds (in Internal Medicine, Haemato-Oncology, Surgery,
Obstetrics–Gynaecology, Neonatology, Paediatrics and the
Intensive Care Units), 301 intermediate-term care beds (in
units receiving patients who require convalescence or physical
therapy) and 500 long-term care beds (where hospitalisation is
> 1 month). During the study period, the mean number of beds
in the hospital was 1700, corresponding to a mean 41 800
admissions ⁄year.
Bacterial isolates
E. coli UTI and colonisation isolates were collected from
1 January 1997 to 30 September 2003. Urine specimens from
outpatient and emergency units were not included in the
analysis for the present study. The genus and species were
determined biochemically with the Vitek 2-AST N017 identi-
ﬁcation card (bioMe´rieux, Marcy-l’Etoile, France). In order to
avoid duplicates, only the ﬁrst E. coli isolate was included from
each patient admitted.
Antibiotic susceptibility testing
The results of susceptibility tests were obtained from the
laboratory computer database for clinical E. coli isolates
between January 1997 and September 2003. The Vitek 2
GNS-F7 card and a disk diffusion assay on Mueller–Hinton
agar (Sanoﬁ Diagnostics Pasteur, Marnes-la-Coquette, France)
were used to test the susceptibility of E. coli isolates to
antibiotics. Isolates were classiﬁed as susceptible (S), interme-
diately resistant (I) or resistant (R) according to the recom-
mendations of the Antibiogram Committee of the French
Society for Microbiology [11]. All non-susceptible isolates
(R + I) were considered as resistant. The following antibiotics
were tested: amoxycillin, amoxycillin–clavulanic acid, ticarcil-
lin, ticarcillin–clavulanic acid, piperacillin, piperacillin–tazo-
bactam, cefepime, cefotaxime, ceftazidime, imipenem,
nalidixic acid, norﬂoxacin, peﬂoxacin, oﬂoxacin, ciproﬂoxacin,
gentamicin, amikacin and trimethoprim–sulphamethoxazole.
Antibiotic consumption
Monthly quantities (g) of all antibiotics were obtained during
the study period from the hospital pharmacy database and
were converted into deﬁned daily doses (DDD) [12]. Antibiotic
consumption was expressed ﬁnally as the number of DDD ⁄
1000 patient-days.
Statistical analysis
The evolving trend of E. coli isolates that were resistant to
antibiotics was assessed using the Cochran–Armitage test for
linear trend. The autoregressive integrated moving average
(ARIMA) models were used to describe E. coli resistance
against oﬂoxacin and ciproﬂoxacin, which were chosen as
examples of ﬂuoroquinolones in the present study. Box and
Jenkins [13] suggested a suitable method to construct ARIMA
models. This method was used to analyse the temporal
behaviour of a given variable, expressed as a function of its
previous values, trends and abrupt changes in the near past.
This approach has been used in medicine to analyse time-
series in various studies [14,15]. Recently, some studies have
employed ARIMA models designed for the descriptive study
of antibiotic resistance and use [10]. DR models were used to
study the relationships between the use of several antibiotics
and resistance to the chosen ﬂuoroquinolones.
DR models were developed as regression models, in which
ARIMA models are used as disturbance, by Pankratz [16].
Construction of an ARIMA model for both the output and the
input series was suggested before attempting to build a DR
model by transfer functions. Linear transfer function (LTF) is
one of several strategies used to build DR models. LTF shows
how an output series (in the present case, antibiotic resistance)
is related to the input series (the use of several antibiotics) by
taking into account possible time-lags (delay of antibiotic
effect). It also takes into consideration the time structure
(autocorrelation pattern) of the disturbance series. In building
ARIMA and DR models, a three-stage model-building strategy
was used, based on model identiﬁcation, model estimation and
model checking. In this article, the DR model-building strategy
is presented. More details of the three-stage model-building
strategy for ARIMA models, including transformation and
differentiation series, can be found elsewhere [10,13,16,17].
In the DR model identiﬁcation stage, LTF enabled a direct
transfer function with a moderate number of lags for the input
series to be built, approaching the stochastic part of the model
using an autoregressive term with a low order. The Augmen-
ted Dickey–Fuller test for Unit Roots was used for transfor-
mations and differentiation diagnosis series (SAS ⁄ETS
software v. 8.1; SAS Institute Inc, Cary, NC, USA). An
appropriate tentative model from the DR family models that
summarises these patterns, and an ARIMA model for the
disturbance, were identiﬁed. In the second stage, parameters
of the identiﬁed tentative model were estimated using a
maximum-likelihood estimation method and SAS ⁄ETS soft-
ware. Regression-type coefﬁcients that represent the input–
output relationship, and ARIMA model coefﬁcients that
represent the disturbance series autocorrelation pattern, were
the parameters estimated with their approximated standard
errors, tests of hypothesis and conﬁdence intervals. The
Akaike Information Criterion of the goodness of ﬁt was
estimated, together with the determination coefﬁcient, R2,
corresponding to the percentage of the variance of the
observed time-series explained by the model. In the model-
checking stage, the adequacy of the ARIMA model for the
disturbance series in the DR model was examined using three
diagnostic checks: (1) statistical signiﬁcance of the parameters;
(2) the checking of autoregressive stationarity parameters and
the moving average invertibility parameters; and (3) the
checking of residuals that effectively corresponded to white
noise [14,15]. Using the adequate DR model, short-term
forecasting of resistance, i.e., up to 8 months, was possible.
The study period was from January 1997 to September 2003,
and the validation period was from October 2003 to May 2004.
In May 2004, the predicted percentage resistance with 95% CI
obtained by the model and the observed percentage resistance
were compared.
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RESULTS
Antibiotic resistance trends
During the study period, 9338 non-duplicate
E. coli urinary tract isolates were collected from
hospitalised patients. The mean age of hospital-
ised patients was 64.1 years (standard deviation,
25.6 years) and 79.0% of the patients were female.
Most (87.7%) patients were in acute-care units,
9.9% were in intermediate-term care units and
2.4% were in long-term care units. Among the
b-lactams tested, the highest mean resistance was
to amoxycillin (51.4%), ticarcillin (46.5%), pipera-
cillin (43.6%) and amoxycillin–clavulanic acid
(30.4%). The lowest rate of resistance (£ 2.0%)
was found for broad-spectrum cephalosporins
(cefotaxime and ceftazidime). No isolates were
resistant to imipenem. Long-term trends in resist-
ance to the b-lactams tested are presented in
Table 1. During the study period, resistance rates
to aminoglycosides were stable and low; thus,
1.0% and 4.1% of isolates were resistant to
amikacin and gentamicin, respectively. A signiﬁ-
cant decrease in the percentage of resistance was
seen for trimethoprim–sulphamethoxazole (30.8–
23.8%), while a signiﬁcant increase in resistance
was noted for the ﬂuoroquinolones studied
(oﬂoxacin and ciproﬂoxacin) (Table 2).
Oﬂoxacin resistance
The observed mean monthly resistance rate was
10.2% ± 3.8%. An ARIMAmodel was built for the
oﬂoxacin resistance percentage during the study
period. The series became stationary after log
transformation and simple differentiation. The
identiﬁed model contained only one signiﬁcant
moving average term of order 1. Table 3A pre-
sents the univariate analysis model, with 0.38 as
the determination coefﬁcient (R2) and 196.6 as the
Akaike Information Criterion. The residual series
corresponded to white noise. During the same
period, the monthly use of oﬂoxacin increased
from 9.4 to 12.9 DDD ⁄ 1000 patient-days (p < 0.05).
An ARIMA model was built for the oﬂoxacin use
series after simple differentiation. LTF allowed DR
analysis for the two series presented in Table 3B.
Multivariate dynamic regression was assessed to
study the relationship between oﬂoxacin use, use
of other quinolones, and impact on the oﬂoxacin
resistance percentage. The parameters used by the
model, presented in Table 3C, were interpreted by
assuming that the present rate of oﬂoxacin resist-
ance was related to an average observed 1 month
previously. An increase of 1 DDD ⁄ 1000 patient-
days for oﬂoxacin resulted, with an average delay
of 4 months, in an increase of 0.81% in the
oﬂoxacin resistance rate after taking into account
the use of ciproﬂoxacin, norﬂoxacin and nalidixic
acid. An increase of 1 DDD ⁄ 1000 patient-days for
ciproﬂoxacin resulted, with an average delay of
4 months, in an increase of 0.65% in oﬂoxacin
resistance, after taking into account the use of
other quinolones. The same interpretation could
be made for 1 DDD ⁄ 1000 patient-days of norﬂ-
oxacin use, which resulted in a 0.53% increase in
resistance, with an average delay of 6 months. The
use of nalidixic acid did not increase oﬂoxacin
resistance signiﬁcantly after taking into account
the use of other quinolones. The introduction of
other antibiotics did not improve the model. The
determination coefﬁcient R2 for the adequate
model was 0.64, which enabled the model to
account for 64% of the observed variations in the
oﬂoxacin resistance series.
This model allowed a short-term forecast of
oﬂoxacin resistance, i.e., up to May 2004 (Fig. 1).
In May 2004, the predicted resistance percentage
Table 1. b-Lactam resistance (% resistant; n) among Escherichia coli urinary isolates collected between January 1997 and
September 2003 from Nıˆmes University Hospital, France
Antibiotic Total 1997 1998 1999 2000 2001 2002 2003 p trend
AMX 51.4 (8885) 50.0 (1366) 51.0 (1426) 51.2 (1444) 51.2 (1359) 49.5 (1161) 55.2 (1277) 53.5 (852) 0.01
AMC 30.4 (9224) 32.5 (1426) 29.0 (1494) 30.2 (1528) 26.1 (1429) 30.4 (1210) 31.8 (1281) 34.9 (856) 0.10
TIC 46.5 (8857) 46.4 (1364) 47.2 (1425) 47.7 (1439) 47.4 (1349) 43.4 (1156) 47.8 (1275) 44.4 (849) 0.30
TIM 9.6 (8780) 8.2 (1302) 9.2 (1422) 8.5 (1436) 7.0 (1351) 7.7 (1153) 12.3 (1271) 16.7 (845) < 0.0001
PIP 43.6 (7218) 40.8 (1361) 43.5 (1422) 45.3 (1441) 45.0 (1355) 41.6 (1162) 46.5 (314) 46.6 (163) 0.13
TZP 3.4 (7440) 4.7 (235) 3.5 (1190) 2.8 (1440) 1.0 (1299) 2.8 (1162) 4.9 (1268) 6.5 (846) < 0.0001
CTX 1.2 (8854) 1.1 (1366) 1.7 (1425) 0.7 (1441) 0.6 (1357) 1.7 (1144) 1.5 (1272) 0.9 (849) 0.80
CAZ 1.5 (8859) 2.1 (1361) 1.6 (1421) 0.9 (1439) 1.1 (1353) 2.2 (1161) 1.6 (1274) 1.1 (850) 0.30
FEP 0.8 (7197) 0.4 (1357) 0.9 (1423) 0.4 (1442) 0.5 (1358) 1.4 (1162) 2.7 (298) 2.5 (157) < 0.0001
IMP 0.0 (8869) 0.0 (1366) 0.0 (1423) 0.0 (1442) 0.0 (1355) 0.0 (1160) 0.0 (1275) 0.0 (848) NS
AMX, amoxycillin; AMC, amoxycillin–clavulanic acid; TIC, ticarcillin; TIM, ticarcillin–clavulanic acid; PIP, piperacillin; TZP, piperacillin–tazobactam; CTX, cefotaxime; CAZ,
ceftazidime; FEP, cefepime; IMP, imipenem; NS, not signiﬁcant.
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was 16.2% (95% CI, 9.6–22.8), while the observed
percentage was 16.4%.
Ciproﬂoxacin resistance
The mean monthly resistance rate was
7.1% ± 2.9% during the study period. An ARIMA
model was built for the ciproﬂoxacin resistance
percentage. The series became stationary after log
transformation and simple differentiation. The
identiﬁed ARIMA model contained only one
signiﬁcant moving average term of order 1. The
estimated parameters in this univariate model are
presented in Table 4A. During the same period,
the monthly use of ciproﬂoxacin increased from
2.0 to 6.1 DDD ⁄ 1000 patient-days (p < 0.05). An
ARIMA model was built for the ciproﬂoxacin use
series after simple differentiation. The impact of
ciproﬂoxacin and the other quinolones used was
analysed using DR models (Table 4C), and inter-
preted by assuming that the present rate of
ciproﬂoxacin resistance is related to an average
observed 1 month previously. An increase of
1 DDD ⁄ 1000 patient-days for ciproﬂoxacin resul-
ted, with an average delay of 4 months, in an
increase of 0.73% in the ciproﬂoxacin resistance
rate, after taking into account the use of oﬂoxacin,
norﬂoxacin and nalidixic acid. An increase of
1 DDD ⁄ 1000 patient-days for oﬂoxacin resulted,
with an average delay of 4 months, in an increase
of 0.82% in ciproﬂoxacin resistance, after taking
into account the use of other quinolones. The same
interpretation could be made for 1 DDD ⁄ 1000
patient-days of norﬂoxacin use, which resulted in
a 0.63% increase in resistance, with an average
Table 2. Quinolones, aminoglycoside and co-trimoxazole resistance (% resistance; n) among Escherichia coli urinary
isolates collected between January 1997 and September 2003 from Nıˆmes University Hospital, France
Antibiotic Total 1997 1998 1999 2000 2001 2002 2003 p trend
NAL 17.3 (8854) 16.4 (1363) 17.1 (1419) 15.4 (1440) 18.3 (1358) 16.7 (1162) 18.7 (1262) 19.2 (850) 0.04
OFX 10.9 (8706) 8.9 (1364) 10.1 (1424) 7.2 (1432) 9.7 (1333) 10.7 (1029) 15.4 (1274) 16.7 (850) < 0.0001
CIP 7.4 (8873) 6.2 (1366) 7.2 (1425) 4.3 (1441) 6.9 (1357) 9.2 (1161) 9.0 (1274) 10.1 (849) < 0.0001
PEF 12.5 (6949) 10.5 (1122) 12.7 (1417) 12.0 (1437) 11.9 (1341) 13.0 (1149) 16.0 (324) 23.2 (159) < 0.0001
GEN 4.1 (8860) 3.5 (1365) 4.7 (1423) 2.8 (1442) 5.0 (1350) 4.8 (1162) 3.5 (1271) 4.6 (847) 0.4
AMK 1.0 (8875) 1.5 (1365) 0.7 (1424) 0.5 (1441) 0.5 (1358) 0.6 (1163) 1.7 (1275) 1.4 (849) 0.3
SXT 29.1 (8863) 30.8 (1364) 33.3 (1424) 29.0 (1438) 30.5 (1354) 28.2 (1161) 25.2 (1273) 23.8 (849) < 0.0001
NAL, nalidixic acid; OFX, oﬂoxacin; CIP, ciproﬂoxacin; PEF, peﬂoxacin; GEN, gentamicin; AMK, amikacin; SXT, co-trimoxazole.
Table 3. ARIMA and transfer function models for estima-
ting percentage resistance of Escherichia coli isolates to
oﬂoxacin (Nıˆmes Hospital, France, 1997–2003)
Antibiotic use Ordera Parameterb (SE) T-ratio p R2 AIC
A. ARIMA model for percentage of oﬂoxacin resistance
MAc 1 0.74 (0.08) 9.65 < 0.0001 0.38 196.6
B. Transfer function for oﬂoxacin resistance, taking into account use of oﬂoxacin
Oﬂoxacin use 4 0.62 (0.30) 2.04 0.04
MA 1 0.86 (0.12) 6.98 < 0.0001 0.46 178.5
C. Transfer function for oﬂoxacin resistance, taking into account use of other
quinolones
Oﬂoxacin use 4 0.81 (0.09) 9.45 < 0.0001
Ciproﬂoxacin use 4 0.65 (0.24) 2.73 < 0.01
Norﬂoxacin use 6 0.53 (0.14) 3.88 < 0.001 0.64 157.8
Nalidixic acid use 8 0.41 (0.27) 1.52 0.13
MA 1 0.76 (0.09) 8.66 < 0.0001
aDelay before effect is observed (months).
bSize and direction of the effect.
cMA: moving average term, representing disturbances and abrupt changes of
resistance.
AIC, Akaike Information Criterion; SE, standard error.
Fig. 1. Monthly percentage of oﬂoxacin-resistant Escherichia coli observed between January 1997 and September 2003, and
predicted values up to May 2004 with 95% conﬁdence intervals according to the ARIMA and transfer function models.
Asterisks represent the observed values between January 1997 and September 2003; the curve represents the predicted
values computed between September 1997 and May 2004.
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delay of 5 months. The use of nalidixic acid did
not increase ciproﬂoxacin resistance signiﬁcantly
when other quinolones were considered. The
determination coefﬁcient, R2, of the model was
0.40, which enabled the model to explain 40% of
the variation in ciproﬂoxacin resistance.
This model allowed a short-term forecast of
ciproﬂoxacin resistance, i.e., up to May 2004
(Fig. 2). In May 2004, the predicted resistance
percentage was 9.9% (95% CI, 4.3–15.4), while the
observed percentage was 12.6%.
DISCUSSION
In the present study, a signiﬁcant increase was
identiﬁed in the frequency of oﬂoxacin- and
ciproﬂoxacin-resistant E. coli urinary isolates
between January 1997 and September 2003. The
rate of resistance reached c. 17% for oﬂoxacin and
10% for ciproﬂoxacin. This trend has been
observed in other studies since the 1990s
[5,18,19], although the resistance rates in the
present study appeared to be slightly higher
because isolates were collected from cases of
UTI and colonisation. In most studies, the major
selective pressure driving changes in bacterial
susceptibility is the volume of antibiotic use. The
widespread use of ﬂuoroquinolones for treatment
or prophylaxis in recent years may have progres-
sively selected resistant E. coli mutants [5,7,20].
An association between the increase in oﬂoxa-
cin-resistant isolates of E. coli and increasing use
of oﬂoxacin, ciproﬂoxacin and norﬂoxacin was
identiﬁed using multivariate DR analysis. No
signiﬁcant association was found between the
use of nalidixic acid and the increase in oﬂoxacin
resistance by multivariate analysis, probably
because nalidixic acid was not used widely in
Nıˆmes University Hospital during the study
period. The determination coefﬁcient, R2, of the
model was 0.64, which enabled the model to
account for 64% of the variations in the oﬂoxacin-
resistant series. The remaining 36% was caused
by infection control practices and other risk
factors described in previous studies [2,4–6,21].
The same association between the use of ﬂuoro-
quinolones (oﬂoxacin, ciproﬂoxacin, norﬂoxacin)
and an increase in ciproﬂoxacin resistance was
identiﬁed. This suggests that use of ﬂuoroquino-
lones was the main factor relating to ﬂuoroqui-
nolone resistance. These ﬁndings have been
conﬁrmed by other studies [22–24].
Table 4. ARIMA and transfer function models used to
estimate percentage resistance of Escherichia coli isolates to
ciproﬂoxacin (Nıˆmes Hospital, France, 1997–2003)
Antibiotic use Ordera Parameterb (SE) T-ratio p R2 AIC
A. ARIMA model for percentage of ciproﬂoxacin resistance
MAc 1 0.81(0.07) 11.9 < 0.0001 0.13 171.1
B. Transfer function for ciproﬂoxacin resistance, taking into account use of
ciproﬂoxacin
Ciproﬂoxacin use 4 0.52(0.21) 2.39 < 0.01
MA 1 0.92(0.12) 7.78 < 0.0001 0.25 152.8
MA 3 ) 0.36(0.12) ) 3.05 < 0.001
C. Transfer function for ciproﬂoxacin resistance, taking into account use of other
quinolones
Ciproﬂoxacin use 4 0.73(0.18) 4.14 < 0.001
Oﬂoxacin use 4 0.82(0.08) 10.51 < 0.0001
Norﬂoxacin use 5 0.63(0.30) 2.07 < 0.05 0.40 148.7
Nalidixic acid use 3 ) 0.09(0.55) ) 0.16 0.87
MA 1 0.81(0.08) 10.27 < 0.0001
aDelay before effect is observed (months).
bSize and direction of the effect.
cMA: moving average term, representing disturbances and abrupt changes of
resistance.
AIC, Akaike Information Criterion; SE, standard error.
Fig. 2. Monthly percentage of
ciproﬂoxacin-resistant Escherichia
coli observed between January 1997
and September 2003, and predicted
values up to May 2004 with 95%
conﬁdence intervals according to the
ARIMA and transfer function mod-
els. Asterisks represent the observed
values between January 1997 and
September 2003; the curve repre-
sents the predicted values computed
between September 1997 and May
2004.
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The relationship between antibiotic resistance
and consumption was studied using multivariate
DR analysis. Unlike linear regression analysis, as
used in other studies that evaluated linear and
concomitant variations between antibiotic use and
resistance [5,8], DR allowed complex temporal
relationships to be analysed and could estimate
the delay between variations in antibiotic use and
subsequent variations in resistance. Furthermore,
the adequate model ﬁtted by DR analysis allowed
forecasts of E. coli resistance based on past
antibiotic use and resistance data. This surveil-
lance system, based on longitudinal data, could
react to changes in antibiotic use and the suscep-
tibility of isolates in this hospital much faster than
other retrospective studies. This study would be
appropriate for pedagogical demonstrations of
rational antibiotic use within the hospital.
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